Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.
暂无分享,去创建一个
I. Grant | D. Clifford | R. Ellis | J. McCutchan | D. Simpson | J. McArthur | S. Letendre | A. Collier | B. Gelman | S. Morgello | E. Capparelli | B. Best | J. Marquie‐Beck
[1] I. Grant,et al. Low atazanavir concentrations in cerebrospinal fluid , 2009, AIDS.
[2] R. Ellis,et al. Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV , 2005, AIDS.
[3] G. Arendt,et al. Cerebrospinal fluid HIV viral load in different phases of HIV–associated brain disease , 2005, Journal of Neurology.
[4] J. Ghersi-Egea,et al. Factors affecting delivery of antiviral drugs to the brain , 2005, Reviews in medical virology.
[5] J. Beijnen,et al. Study on didanosine concentrations in cerebrospinal fluid , 1995, Pharmacy World and Science.
[6] I. Grant,et al. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders , 2004, Annals of neurology.
[7] K. Hertogs,et al. Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration , 2003, AIDS.
[8] C. Marra,et al. Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy , 2003, Neurology.
[9] C. Solas,et al. Discrepancies between Protease Inhibitor Concentrations and Viral Load in Reservoirs and Sanctuary Sites in Human Immunodeficiency Virus-Infected Patients , 2003, Antimicrobial Agents and Chemotherapy.
[10] M. Capobianchi,et al. Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients , 2002, AIDS.
[11] A. De Luca,et al. Correlates of independent HIV-1 replication in the CNS and of its control by antiretrovirals , 2002, Neurology.
[12] C. Solas,et al. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: Clinical correlations , 2002, HIV clinical trials.
[13] P. Portegies,et al. Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy. , 2000 .
[14] P. Portegies,et al. Increasing Cerebrospinal Fluid Chemokine Concentrations Despite Undetectable Cerebrospinal Fluid HIV RNA in HIV‐1‐Infected Patients Receiving Antiretroviral Therapy , 2000, Journal of acquired immune deficiency syndromes.
[15] S. Staprans,et al. Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1--infected patients with and without AIDS dementia complex. , 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[16] L. Dunkle,et al. A single-dose study to assess the penetration of stavudine into human cerebrospinal fluid in adults. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[17] S. Larson,et al. RESPONSE OF HUMAN-IMMUNODEFICIENCY-VIRUS-ASSOCIATED NEUROLOGICAL DISEASE TO 3'-AZIDO-3'-DEOXYTHYMIDINE , 1987, The Lancet.